The Board of Cann Global Limited (ASX:CGB) is pleased to announce that its T12 Food Division, under managers Sebastian and Samuel Edwards, has become an official supplier to Costco.

Cann Global Limited (ASX:CGB) provides the following update in relation to CGB's Nutraceutical manufacturing schedule and the Israeli based Pharmocann formulator's visit to Australia.

The suspension of trading in the securities of Cann Global Limited (ASX:CGB) is expected to lift and the Company reinstated to official quotation at the commencement of trading on Friday 23 August 2019

Cann Global Limited (ASX:CGB) provides the following update in connection with the reinstatement to quotation of the Company's fully paid Ordinary Shares.

Cann Global Limited (ASX:CGB) provides the following update in connection with the reinstatement to quotation of the Company's fully paid Ordinary Shares.

As foreshadowed in the Company's announcement dated 15 May 2019, Cann Global Limted (ASX:CGB) confirms that the appointments of David Austin, Jonathan Cohen and John Easterling as independent directors took effect upon approval by Shareholders at the 2 July 2019 General Meeting.

Cann Global Limited (ASX:CGB) is pleased to advise that the company is in the process of providing the ASX with all the paperwork confirming completion of all the transactions, completion of all the share issues, receipt of all the required escrow agreements, and the related required relisting documentation.

YPB Group Ltd (ASX:YPB) provides the Company's financial results commentary.

Product authenticity and consumer engagement solutions provider YPB Group Ltd (ASX:YPB) is excited to announce that existing distribution partner and e-commerce leader in the cannabis market, Namaste Technologies (CVE:N), has agreed to broaden the use of YPB's product markers to all products on Namaste's e-commerce platforms.

Oventus Medical Ltd (ASX:OVN) is pleased to announce the Canadian launch of the O2Vent(R) Optima device which treats both the potentially fatal condition, obstructive sleep apnoea and snoring. The device launch in Canada follows the successful completion of a controlled market release, with early results demonstrating strong patient acceptance.